Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Reports $10.2 Million in Income for Q4

NEW YORK, Feb. 14 - Invitrogen yesterday reported its second-straight profitable quarter, bolstered by a slight revenue increase and continued expense cutting.


For the period ended Dec. 31, the company's revenues totaled $161.8 million, compared to $153.3 million for the year-ago period. At the same time, R&D expenditures increased slightly to $9.7 million, from $9.5 million in the fourth quarter of 2001, while overall operating expenses decreased to $80.7 million, from $118.3 million year over year.


The company earned a net income of $10.2 million, or $.20 per share in the fourth quarter, compared to losses of $35.6 million, or $.67 per share for the year-ago quarter. As it said last quarter, Invitrogen again reported that the single largest factor contributing to its move into the black was the implementation of an accounting rule, SFAS No. 142, which no longer allows the amortization of goodwill.


As of December 31, 2002, the company had $537.8 million in cash and cash equivalents, compared to $878.2 million at the end of the fourth quarter of 2001. (The company's short-term investments increased, however, to $184.2 million, from $99.6 million as of December 31, 2001.)






The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.